Vertex Pharmaceuticals Option Alert: Jan, 2027 $550 Calls at the Bid: 250 vs 134 OI; Earnings 8/4 After Close 

Vertex Pharmaceuticals Option Alert: Jan, 2027 $550 Calls at the Bid: 250 @ $51.5 vs 134 OI; Earnings 8/4 After Close Ref=$471.85

Vertex Pharmaceuticals Bolsa (NASDAQ: VRTX)

Vertex Pharmaceuticals (NASDAQ:VRTX) Bolsa

VERTEX PHARMACEUTICALS INC

Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Crispr Therapeutics

Health Care

Markets

ARKG

ARKK

CRSP

MSFT

VRTX

Cathie Wood señala dos acciones biotecnológicas con potencial de crecimiento explosivo gracias a la revolución genética y la IA.

Cathie Wood apuesta por la biotecnología: estas dos acciones podrían multiplicarse por diez

Earnings

Long Ideas

News

Pre-Market Outlook

Trading Ideas

VOXX

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este lunes: MCD, ON, VOXX, ROK y VRTX.

5 acciones en el foco este lunes: MCD, ON, VOXX, ROK y VRTX

Equities

ETFs

$BTC

ARKF

ARKW

COIN

EXAS

PLTR

PSNL

El miércoles, Cathie Wood, a la cabeza de Ark Invest, realizó algunas operaciones significativas, siendo las más destacadas las de Coinbase Global Inc (NASDAQ:COIN) y Palantir Technologies Inc (NYSE:

Movimientos clave de Cathie Wood: ¿qué hay detrás de las últimas operaciones de Ark Invest?

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals Inc

- In head-to-head clinical trials, ALYFTREK was non-inferior on ppFEV1&nbsp;and superior in reducing sweat chloride compared to TRIKAFTA&nbsp;-
-&nbsp; Approximately 3,800 people in Canada are now eligible for ALYFTREK, with up to 60 people potentially eligible for a medicine that treats the underlying cause of their disease for the first time -
TORONTO, July 22, 2025 /CNW/ - <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4472390-1&amp;h=4238511807&amp;u=https%3A%2F%2Fwww.vrtx.com%2Fen-ca%2F&amp;a=Vertex+Pharmaceuticals">Vertex Pharmaceuticals</a> today announced that Health Canada has granted Marketing Authorization for PrALYFTREKTM&nbsp;(vanzacaftor/tezacaftor/deutivacaftor), a new triple combination therapy for patients living with cystic fibrosis (CF) ages 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
ALYFTREK brings a potentially transformative therapy to up to 60 people living with CF in Canada who were not previously eligible for a CFTR modulator. As the first once-daily CFTR modulator, ALYFTREK may also provide a new treatment option and flexibility for approximately 3,800 people given the need to take CFTR modulators with fat-containing food.
ALYFTREK is currently approved in the U.S., UK and European Union and is under regulatory review in Switzerland, Australia and New Zealand.&nbsp;
 &nbsp;

Vertex Pharma's ALYFTREK Approved By Health Canada For Cystic Fibrosis Treatment In Children And Adults With Responsive CFTR Mutations

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 10 years by 1.83% on an annualized basis producing an average annual return of 13.39%. Currently, Vertex Pharmaceuticals has a market capitalization of $118.08 billion. 
Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 10 years ago, it would be worth $3,509.46 today based on a price of $459.81 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752881411_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today

Biotech

Large Cap

General

Monday, Vertex Pharmaceuticals Reached A Broad Reimbursement Agreement With NHS England For Vertex's Cystic Fibrosis Medicine Alyftrek (Deutivacaftor/Tezacaftor/Vanzacaftor)

JP Morgan analyst Jessica Fye maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Overweight and raises the price target from $515 to $517.

Price Target

Analyst Ratings

JP Morgan Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $517

Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals.
Looking at options history for Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) we detected 11 trades.
If we consider the specifics of each trade, it is accurate to state that 9% of the investors opened trades with bullish expectations and 63% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $241,517 and 5, calls, for a total amount of $8,715,760.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $475.0 to $500.0 for Vertex Pharmaceuticals over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Vertex Pharmaceuticals stands at 1663.0, with a total volume reaching 3,306.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Vertex Pharmaceuticals, situated within the strike price corridor from $475.0 to $500.0, throughout the last 30 days.
<h3>Vertex Pharmaceuticals Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752242469_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/17/27</td>
<td>$92.0</td>
<td>$85.3</td>
<td>$86.0</td>
<td>$500.00</td>
<td>$3.4M</td>
<td>3.3K</td>
<td>1.1K</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/17/27</td>
<td>$88.5</td>
<td>$86.1</td>
<td>$88.5</td>
<td>$500.00</td>
<td>$2.2M</td>
<td>3.3K</td>
<td>513</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/17/27</td>
<td>$93.7</td>
<td>$88.2</td>
<td>$88.1</td>
<td>$500.00</td>
<td>$1.3M</td>
<td>3.3K</td>
<td>702</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/17/27</td>
<td>$88.7</td>
<td>$84.6</td>
<td>$88.7</td>
<td>$500.00</td>
<td>$887.0K</td>
<td>3.3K</td>
<td>202</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/17/27</td>
<td>$96.5</td>
<td>$87.1</td>
<td>$87.0</td>
<td>$500.00</td>
<td>$870.0K</td>
<td>3.3K</td>
<td>100</td>
</tr>
</tbody>
</table>

<h3>About Vertex Pharmaceuticals</h3>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Following our analysis of the options activities associated with Vertex Pharmaceuticals, we pivot to a closer look at the company's own performance.
<h3>Where Is Vertex Pharmaceuticals Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 93,478, the VRTX's price is down by 0.0%, now at $479.53. </li>
<li>RSI readings suggest the stock is currently may be approaching overbought.</li>
<li>Anticipated earnings release is in 24 days.</li>
</ul>
<h3>Professional Analyst Ratings for Vertex Pharmaceuticals</h3>
A total of 3 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $476.67.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on Vertex Pharmaceuticals with a target price of $420. 
&#x2A; An analyst from HC Wainwright &amp; Co. downgraded its action to Buy with a price target of $550. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Vertex Pharmaceuticals with a target price of $460. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Vertex Pharmaceuticals with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Options

Vertex Pharmaceuticals's Options: A Look at What the Big Money is Thinking

- Data from longer-term follow-up of patients in ongoing clinical trials further demonstrate durability of the clinical benefits of CASGEVY&#xAE; -
- Multiple reimbursement agreements secured, expanding access to CASGEVY to more patients around the world -
TORONTO, July 3, 2025 /CNW/ - <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4462066-1&amp;h=2284321717&amp;u=https%3A%2F%2Fwww.vrtx.ca%2F&amp;a=Vertex+Pharmaceuticals">Vertex Pharmaceuticals</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) recently announced positive longer-term data for PrCASGEVY&#xAE; (exagamglogene autotemcel) from global ongoing pivotal clinical trials in people&nbsp;with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented at the European Hematology Association (EHA) Congress,&nbsp;continue to demonstrate the durable clinical benefits of CASGEVY. The longest follow up in SCD patients now extends more than 5.5 years and in TDT patients more than 6 years, with a mean of 39.4 months and 43.5 months, respectively. CASGEVY is the first authorized CRISPR/Cas9 gene-edited therapy.

Vertex's CASGEVY Shows Over 5.5 Years Of Durable Benefit In Sickle Cell And Beta Thalassemia Trials Presented At The EHA Congress; Multiple Reimbursement Agreements Secured

<ul>
<li>ALYFTREK (deutivacaftor/tezacaftor/vanzacaftor) approved in the EU for people with CF 6 years and older with at least one non-class I mutation in the CFTR gene, making it the broadest label for this medicine in the world.</li>
<li>In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride, demonstrating greater improvement in CFTR function.</li>
<li>Approximately 31,000 people with CF in the EU are now eligible for this new highly effective modulator therapy.</li>
</ul>

The European Commission Approves Vertex Pharmaceuticals' Alyftrek (Deutivacaftor/Tezacaftor/Vanzacaftor) For Cystic Fibrosis Patients Ages 6 Years And Older Who Have At Least One Non-class I Mutation In The Cystic Fibrosis Transmembrane Conductance Regulator Gene

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 10 years by 1.82% on an annualized basis producing an average annual return of 13.32%. Currently, Vertex Pharmaceuticals has a market capitalization of $114.33 billion. 
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 10 years ago, it would be worth $345.57 today based on a price of $445.20 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751323514_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today

Vertex Pharmaceuticals's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NYSE">VRTX</a>) short percent of float has fallen 8.76% since its last report. The company recently reported that it has 4.03 million shares sold short, which is 1.77% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.59 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Vertex Pharmaceuticals Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751036461_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Vertex Pharmaceuticals has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Vertex Pharmaceuticals's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Vertex Pharmaceuticals's peer group average for short interest as a percentage of float is 6.62%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Do Investors Really Feel About Vertex Pharmaceuticals?

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VRTX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 21 uncommon options trades for Vertex Pharmaceuticals.
This isn't normal.
The overall sentiment of these big-money traders is split between 42% bullish and 33%, bearish.
Out of all of the special options we uncovered, 11 are puts, for a total amount of $916,872, and 10 are calls, for a total amount of $306,700.
<h3>Expected Price Movements</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $300.0 to $580.0 for Vertex Pharmaceuticals over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for Vertex Pharmaceuticals options trades today is 82.0 with a total volume of 780.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Vertex Pharmaceuticals's big money trades within a strike price range of $300.0 to $580.0 over the last 30 days.
<h3>Vertex Pharmaceuticals Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750968061_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$39.1</td>
<td>$37.6</td>
<td>$37.6</td>
<td>$470.00</td>
<td>$229.3K</td>
<td align="right">74</td>
<td align="right">61</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$55.4</td>
<td>$51.6</td>
<td>$51.6</td>
<td>$490.00</td>
<td>$175.4K</td>
<td align="right">94</td>
<td align="right">34</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$27.4</td>
<td>$25.7</td>
<td>$25.8</td>
<td>$450.00</td>
<td>$64.5K</td>
<td align="right">149</td>
<td align="right">34</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$103.0</td>
<td>$94.7</td>
<td>$101.11</td>
<td>$510.00</td>
<td>$60.6K</td>
<td align="right">109</td>
<td align="right">20</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$102.9</td>
<td>$94.8</td>
<td>$101.02</td>
<td>$510.00</td>
<td>$60.6K</td>
<td align="right">109</td>
<td align="right">26</td>
</tr>
</tbody>
</table>

<h3>About Vertex Pharmaceuticals</h3>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
After a thorough review of the options trading surrounding Vertex Pharmaceuticals, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of Vertex Pharmaceuticals</h3>
<ul>
<li>Currently trading with a volume of 808,929, the VRTX's price is down by -0.9%, now at $441.81. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 35 days.</li>
</ul>
<h3>Professional Analyst Ratings for Vertex Pharmaceuticals</h3>
In the last month, 3 experts released ratings on this stock with an average target price of $476.67.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Reflecting concerns, an analyst from HC Wainwright &amp; Co. lowers its rating to Buy with a new price target of $550. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Vertex Pharmaceuticals with a target price of $460. 
&#x2A; Maintaining their stance, an analyst from RBC Capital continues to hold a Sector Perform rating for Vertex Pharmaceuticals, targeting a price of $420. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Vertex Pharmaceuticals, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Vertex Pharmaceuticals Unusual Options Activity

Reuters Cites U.S. Health Secretary Kennedy Saying Doing Everything We Can Across Department To Promote Access To Non-Opioid Pain Reliever Journavx

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Buy and maintains $550 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Vertex Pharmaceuticals, Maintains $550 Price Target

OPHLY

Vertex And Ono Pharmaceutical Forge Strategic Partnership To Advance Povetaciceptiin In Japan and South Korea For IgA And Membranous Nephropathy

Reported Friday, Vertex's Zimislecel Shows Durable Insulin Independence In 10 Of 12 Patients With Type 1 Diabetes, All Achieve ADA Glycemic Targets

The U.S. Food and Drug Administration (FDA) on Wednesday initiated <a href="https://www.fda.gov/news-events/press-announcements/fda-halts-new-clinical-trials-export-americans-cells-foreign-labs-hostile-countries-genetic">an immediate review</a> of clinical trials that involved sending Americans&#8217; living cells to China and other foreign adversaries for genetic engineering and subsequent infusion back into U.S. patients, sometimes <a href="https://www.benzinga.com/general/health-care">without their knowledge or consent</a>.
The <a target="_blank" href="https://www.nih.gov/news-events/news-releases/fda-halts-new-clinical-trials-export-americans-cells-foreign-labs-hostile-countries-genetic-engineering" rel="noreferrer noopener">move</a> comes amid growing concern over the security and ethics of cross-border biomedical research and the handling of sensitive genetic data.
Mounting evidence has shown that some clinical trials failed to inform participants that their biological samples would be transferred abroad, raising red flags about consent and potential misuse of genetic information by foreign governments.
Also Read: <a href="https://www.benzinga.com/news/fda/25/06/45982666/fda-introduces-tumor-board-style-reviews-for-faster-drug-decisions" target="_blank" rel="noreferrer noopener">FDA Introduces Tumor Board-Style Reviews For Faster Drug Decisions</a>
The practice became possible after the Biden Administration approved a sweeping exemption in late 2024, enabling U.S. companies to export biological samples for processing abroad, even in trials regulated by the FDA.
While the original intent of a 2024 data security rule was to limit data transfers to countries of concern, the exemption, implemented in April 2025, allowed exceptions even for companies partially owned or influenced by the Chinese Communist Party.
FDA Commissioner Dr. Marty Makary criticized the policy, &#8220;The previous administration turned a blind eye and allowed American DNA to be sent abroad, often without the knowledge or understanding of trial participants.&#8221; He emphasized the need to protect patient privacy and restore confidence in U.S. biomedical research.
As part of its response, the FDA will now require companies involved in such trials to prove full transparency, obtain ethical consent, and ensure domestic processing of biological material. New trials failing to meet these standards will not be allowed to proceed.
The agency is coordinating closely with the National Institutes of Health (NIH) to examine federally funded research for any links to the exemption.
NIH Director Dr. Jay Bhattacharya confirmed the agency is conducting a portfolio-wide review to assess whether any NIH-supported trials were affected.
&#8220;In light of the FDA&#8217;s actions and new information surrounding the Biden Administration&#8217;s egregious policies, the National Institutes of Health is actively reviewing its entire research portfolio to determine whether any federally funded clinical trials utilized the exemption issued under the Biden Administration that allowed American biological materials to be sent abroad for genetic modification, particularly to entities operating in countries of concern,&#8221; Bhattacharya said in a statement on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45326322/trump-appointed-martin-makary-targets-faster-drug-approvals-with-fda-artificial-intelligence-overhaul" target="_blank" rel="noreferrer noopener">Trump Appointed Martin Makary Targets Faster Drug Approvals With FDA Artificial Intelligence Overhaul</a></li>
</ul>
Photo by Tada Images via Shutterstock

CRBU

NTLA

SANA

FDA Halts Trials Exporting Americans' Cells To Hostile Countries For Genetic Engineering

Morgan Stanley analyst Matthew Harrison maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Equal-Weight and lowers the price target from $464 to $460.

Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Lowers Price Target to $460

Throughout the last three months, 10 analysts have evaluated Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $482.4, with a high estimate of $567.00 and a low estimate of $420.00. This current average reflects an increase of 0.62% from the previous average price target of $479.44. 
<img src="https://www.benzinga.com/files/images/story/2025/1750183256_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Vertex Pharmaceuticals among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$420.00</td>
<td>$423.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$423.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$442.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$464.00</td>
<td>$462.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$515.00</td>
<td>$512.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$535.00</td>
<td>$535.00</td>
</tr>
<tr>
<td>David Risinger</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$503.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$535.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$420.00</td>
<td>$408.00</td>
</tr>
<tr>
<td>Ying Huang</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$567.00</td>
<td>$555.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vertex Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Vertex Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Vertex Pharmaceuticals's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VRTX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Vertex Pharmaceuticals analyst ratings.</a>
<h2>About Vertex Pharmaceuticals</h2>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
<h3>Vertex Pharmaceuticals: Financial Performance Dissected</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Vertex Pharmaceuticals displayed positive results in 3M. As of 31 March, 2025, the company achieved a solid revenue growth rate of approximately 2.96%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Vertex Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 23.33%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Vertex Pharmaceuticals's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.93%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.85%, the company showcases effective utilization of assets.
Debt Management: Vertex Pharmaceuticals's debt-to-equity ratio is below the industry average at 0.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Vertex Pharmaceuticals Through 10 Analysts

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and lowers the price target from $423 to $420.

RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Lowers Price Target to $420

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 10 years by 2.68% on an annualized basis producing an average annual return of 13.76%. Currently, Vertex Pharmaceuticals has a market capitalization of $114.96 billion. 
Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 10 years ago, it would be worth $3,624.96 today based on a price of $447.67 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749572112_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today

ARK Invest founder Cathie Wood is betting big on a new frontier in biotechnology, one she says could unlock massive market opportunity, and two companies are already leading the way, with the potential to grow 10x from their current levels.
What Happened: Speaking on The Diary of a CEO podcast last week, Wood said the convergence of gene sequencing, artificial intelligence and CRISPR gene editing is beginning to cure diseases previously thought untreatable, and it&#8217;s already generating revenue.
&#8220;This is already beginning to happen,&#8221; Wood said. &#8220;We are able to diagnose cancer with a blood test in Stage 1,&#8221; and even before stage 1 she says, adding that if cancer was discovered in &#8220;Stage 1,&#8221; it can save most people. 
Wood highlighted CRISPR Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>) and Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) as key beneficiaries of this shift. The two companies co-developed Casgevy, a therapy now approved to treat sickle cell disease and beta thalassemia with a single dose.
See Also: <a href="https://www.benzinga.com/markets/tech/25/06/45831309/why-jeff-bezos-might-emerge-as-the-biggest-winner-in-the-trump-musk-feud">Why Jeff Bezos Might Emerge As The Biggest Winner In The Trump-Musk Feud?</a>
&#8220;There's huge demand,&#8221; Wood said, pointing to the severe burden patients suffering from sickle cell disease and beta thalassemia face from repeated hospitalizations. &#8220;Of course they're going to go through a tough regimen, they want to live a more normal life.&#8221;
Casgevy, she says was approved by U.S. and U.K. regulators in late 2023 and is already generating revenue for both firms. Wood believes this marks the beginning of a longer-term transformation in health care economics, where curative, one-time treatments could replace recurring drug regimens, disrupting traditional pharma revenue models.
Wood concluded by saying the she believes these technologies will go up &#8220;more than tenfold in the next five to 10 years,&#8221; adding that &#8220;the opportunities are going to be enormous.&#8221;
Why It Matters: Ark Invest has been a <a href="https://www.benzinga.com/general/biotech/24/11/42206182/cathie-wood-sees-400b-opportunity-in-biologics-how-have-her-bets-fared">proponent of AI and biologic</a>s for the past several years, having called it a $400 billion opportunity just last year. 
Several other prominent experts and entrepreneurs have <a href="https://www.benzinga.com/general/biotech/23/02/30749615/bill-gates-gets-excited-about-future-of-tech-that-has-revolutionized-health-over-past-decade">espoused similar views</a>. This includes Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) founder Bill Gates, who said that CRISPR techonlogy had already &#8220;revolutionized health over the past decade,&#8221; adding that he was excited to see how it will evolve and intersect with other technologies. 
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td class="has-text-align-center" data-align="center">Stock / ETF</td>
<td class="has-text-align-center" data-align="center">Year-To-Date Performance</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">CRISPR Therapeutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>)</td>
<td class="has-text-align-center" data-align="center">+1.04%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>)</td>
<td class="has-text-align-center" data-align="center">+11.03%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)</td>
<td class="has-text-align-center" data-align="center">-4.82%</td>
</tr>
<tr>
<td class="has-text-align-center" data-align="center">ARK Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#BATS">ARKK</a>)</td>
<td class="has-text-align-center" data-align="center">+7.45%</td>
</tr>
</tbody>
</table>
</figure>
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="148" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09055452/Screenshot-2025-06-09-at-3.24.39-PM-1024x148.png" alt="" class="wp-image-942918" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09055452/Screenshot-2025-06-09-at-3.24.39-PM-1024x148.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09055452/Screenshot-2025-06-09-at-3.24.39-PM-300x43.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09055452/Screenshot-2025-06-09-at-3.24.39-PM-768x111.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/09055452/Screenshot-2025-06-09-at-3.24.39-PM.png 1522w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
According to Benzinga&#8217;s Edge Stock Rankings, Crispr Therapeutics scores poorly across the board. While it does have a favorable price trend in the short and medium-terms, <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">here&#8217;s</a> how it compares with Vertex, and other promising biotech stocks. 
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="World Leading Investing Expert: The Big Shift Is Coming! This Investment Could 15x in 5 Years!" width="500" height="281" src="https://www.youtube.com/embed/ZznpMh0DegE?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45831613/collapse-in-immigration-poses-a-bigger-economic-threat-than-trumps-tariffs-warns-deutsche-bank-negative-supply-shock-is-not-good-news-for-a-currency">&#8216;Collapse In Immigration&#8217; Poses A Bigger Economic Threat Than Trump&#8217;s Tariffs, Warns Deutsche Bank: &#8216;Negative Supply Shock Is Not Good News For A Currency&#8217;</a></li>
</ul>
Photo courtesy: T. Schneider / Shutterstock.com

Cathie Wood Just Flagged The Start Of A Biotech Revolution: These 2 Stocks With 10x Potential Are Leading It

Press Releases

NanoViricides (NNVC) to Unveil 'Escape-Proof' Antiviral Platform at Major Biotech Convention

Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference

Vertex Presents Positive Data for Zimislecel in Type 1 Diabetes at the American Diabetes Association 85th Scientific Sessions

Vertex and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea

Vertex Presents Longer-Term Data at the 2025 European Hematology Association (EHA) Congress Demonstrating Durability of CASGEVY® and Provides Update on Expanding Global Access to CASGEVY

Small Cap

Opinion

Precision Genetic Medicine Platform Could Disrupt Standard of Care in Metastatic Cancer, Other Indications of Unmet Needs

Vertex to Announce Second Quarter 2025 Financial Results on August 4th

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis

CGON

CLDI

CTMX

IBRX

MRNA

NNVC

REGN

RHHBY

SMMT

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

BridgeBio Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

BioNTech

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Summit Therapeutics

United Therapeutics Corporation - Common Stock

Comments

Vertex Pharmaceuticals

Unusual Options Activity for

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL